庞其军赵颖△ 郗艳国段世博李国京.miR-134在人垂体腺瘤组织中的表达及其意义*[J].现代生物医学进展英文版,2014,14(17):3328-3333. |
miR-134在人垂体腺瘤组织中的表达及其意义* |
Expression and Significance of miR-134 in the Tissuesof Hypophyseal Adenoma* |
|
DOI: |
中文关键词: 无功能垂体腺瘤 miR-134 增殖侵袭能力 |
英文关键词: Nonfunctional pituitary adenoma miR-134 Proliferation and invasion |
基金项目:河北省自然科学基金项目(C2005000698) |
|
Hits: 772 |
Download times: 435 |
中文摘要: |
摘要目的:探讨垂体腺瘤患者miR-134 的表达及意义,分析其表达水平与无功能垂体腺瘤(non-functioningpituitaryadenomas,
NFPA)增殖侵袭能力的相关性。方法:选择2010 年6 月至2013 年7 月本院收集垂体腺瘤标本104 例以及8 例尸检正常腺垂体的
临床资料。采用实时荧光定量PCR、免疫组织化学技术检测Ki-67、MEG3、miR-134等在NFPA组织中的表达水平,并分析数据。
结果:miR-134在NFPA组织中表达水平显著低于正常腺垂体和其他类型垂体腺瘤(P<0.01);miR-134 的表达水平与NFPA 患者
肿瘤侵袭性、肿瘤细胞Ki-67 阳性率及发病年龄呈负相关(P<0.01)。结论:miR-134 表达下调可能是NFPA肿瘤发生及肿瘤呈侵袭
样生长的重要因素,miR-134 可作为诊断和评估NFPA 预后的参考指标。 |
英文摘要: |
ABSTRACT Objective:To detect the expression of miR-134 in normal pituitary tissue and each pituitary adenomas subtype, and to
analyze the correlation between its expression level and the proliferation and invasion of non-functioning pituitary adenoma (NFPA).
Methods:To collect 104 cases with pituitary adenoma specimens (10 for ACTH adenoma, 18 for GH adenoma, 10 for PRL adenoma,
namely, 66 cases of NFPA)and 8 cases of autopsy normal pituitary and clinically relevant information. To use experimental techniques
such as immunohistochemistry, quantitative real-time fluorescence PCR (qRT-PCR) and so on to detect the expression level of Ki-67,
MEG3 andmiR-134, etc in each specimen, and then analyze the date in combination with clinical data. Results:The expression level of
miR-134 in NFPA is significantly lower than that of other types of pituitary adenomas and normal pituitary (P<0.01) while there exists
negative correlation between the expression level of miR-134 and NFPA patients' age, the positive rate of tumor cells Ki-67 as well as
tumor invasion (P<0.01).Conclusion: The down-regulation of miR-134 may be one of the important causes for the ocurrence and growth
of NFPA tumors,.miR-134 is expected to be a new target for the treatment of NFPA. |
View Full Text
View/Add Comment Download reader |
Close |